GLP1R and type 2 diabetes mellitus: Exenatide is a GLP-1 receptor agonist approved for the treatment of type 2 diabetes mellitus (T2DM) [17] and has been associated with improvements in systolic BP (SBP) in long-term clinical trials [18-22].